NCT00537277View on ClinicalTrials.gov

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs

PHASE4CompletedINTERVENTIONAL

Enrollment

161

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart

Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)

Trial Locations (1)

343662

Istanbul

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY